Taurochenodeoxycholic Acid Test

Bile acids are not just digestive helpers. They are signaling molecules that move between your liver, gut, and bloodstream, telling your body how to handle fat, sugar, and cholesterol. Taurochenodeoxycholic acid (TCDCA) is one of the more interesting members of this family, and its level in stool offers a glimpse into how well your gut is recycling these molecules and how your microbiome is shaping them.

This is a research-grade measurement, not a guideline-driven test. There is no universal cutpoint that flags disease. What it can do is add a layer of context when something feels off in your gut, your liver enzymes, or your metabolic numbers, and there is a real pattern emerging in the science that connects this specific bile acid to liver disease, metabolic risk, and gut function.

What TCDCA Actually Is

Your liver makes a primary bile acid called chenodeoxycholic acid (CDCA) out of cholesterol. To get it ready for work in your gut, the liver attaches an amino acid called taurine to it, producing TCDCA. This conjugated form is then released into bile, helps emulsify the fats you eat, and is mostly reabsorbed in the lower part of your small intestine and recycled back to the liver. A small fraction escapes into the colon, where gut bacteria can transform it further or pass it through into stool.

Beyond digestion, TCDCA acts on receptors (mainly FXR and TGR5) that influence blood sugar control, fat metabolism, blood pressure, and inflammation. FXR is a nuclear receptor that helps regulate bile acid, fat, and glucose handling, while TGR5 is a cell-surface receptor that affects energy use and inflammation. That is why bile acid biology has become so interesting to longevity-minded medicine: these molecules sit at the intersection of liver health, the microbiome, and cardiometabolic risk.

Stool TCDCA Versus Blood TCDCA

Most of the published research on TCDCA measures it in serum or plasma, not stool. The two are biologically related but not interchangeable. A blood reading tells you what is circulating after liver release and gut reabsorption. A stool reading tells you what made it past the recycling step and how the colon and microbiome are handling it. When you see the disease associations described below, assume they come from blood-based studies unless stated otherwise. Whether stool TCDCA tracks the same patterns has not been studied as thoroughly.

Liver Disease Connections

Across many human cohorts, blood TCDCA tends to climb sharply when the liver is struggling. In one analysis using a validated lab method, average serum TCDCA in healthy adults was about 86 ng/mL, while people with liver disease ran roughly 50 times higher at around 4,585 ng/mL. People with acetaminophen-induced liver injury averaged about 5,217 ng/mL. As a stand-alone marker for liver injury, serum TCDCA had a discriminative score (AUC) of 0.874, where 1.0 would be perfect separation.

Conjugated bile acids including TCDCA also rise in fatty liver disease (MASLD/NAFLD), alcohol-associated liver disease, biliary atresia, and chronic hepatitis B. In hepatitis B-related liver disease, panels built around TCDCA-related bile acids separated healthy people from disease with discrimination scores between 0.880 and 1.000, beating standard liver enzymes alone for some comparisons. The pattern across these conditions is consistent: as liver function declines and bile flow gets disrupted, conjugated bile acids back up into the circulation.

Metabolic and Diabetes Risk

In a prospective Chinese study of more than 54,000 adults who started out with normal blood sugar, baseline blood bile acid profiles, including higher conjugated species like TCDCA, predicted a higher likelihood of developing type 2 diabetes years later. The signal was independent enough from standard metabolic markers to suggest bile acid biology contributes to diabetes risk on its own.

On the flip side, the POUNDS Lost trial randomized over 500 overweight adults to weight-loss diets and tracked them for two years. People whose blood TCDCA dropped during weight loss saw bigger improvements in fasting glucose, insulin, insulin resistance scores, lipids, and overall heart disease risk estimates. This suggests TCDCA is not just a passive marker but moves with the underlying metabolic shift.

Cholangiocarcinoma and Biliary Disease

In a case-control study, plasma TCDCA was dramatically higher in those with cholangiocarcinoma (a bile duct cancer) compared with people who had benign biliary conditions. After adjustment, the odds of having cholangiocarcinoma at the highest TCDCA levels were many times those at the lowest, a stronger separation than most single biomarkers achieve. This is not a screening test for the general population, but it points to how disrupted bile acid handling shows up in this cancer.

TCDCA is also elevated in bile from people with gallstone disease, where the broader bile acid composition shifts in ways that may help explain stone formation.

Bile Acid Diarrhea and Gut Function

Higher fecal bile acids can reflect impaired reabsorption in the lower small intestine, a condition called bile acid diarrhea or bile acid malabsorption. In people with chronic watery diarrhea, related bile acid markers (specifically a precursor called C4 and the gut hormone FGF19) have well-validated diagnostic cutoffs. Stool-based bile acid panels including TCDCA are part of a newer set of tools used to evaluate the same problem from a different angle. In inflammatory bowel disease, fecal taurine-conjugated bile acids have been detected at higher rates than in healthy controls, though this is descriptive rather than diagnostic.

Kidney Disease and the Vascular System

In people on hemodialysis for end-stage kidney disease, blood TCDCA runs higher and tracks with worse outcomes. Separately, animal and cell-based studies suggest TCDCA may have protective effects against blood vessel dysfunction tied to obesity, signaling through FXR pathways. This is the rare biomarker where the same molecule appears as both a marker of disease (when chronically elevated due to liver or kidney problems) and as a potentially beneficial signaling molecule in the right context. The protective vascular effects are based largely on preclinical evidence and have not yet been confirmed in clinical trials.

Reading the Counterintuitive Pattern

Holding two ideas at once: chronically elevated TCDCA in blood often reflects liver, kidney, or biliary trouble, while TCDCA acting locally on blood vessels may be protective in preclinical models. That is not a contradiction. It means TCDCA is a context-dependent signal. The level alone does not tell you whether the molecule is doing good or bad work. What matters is the pattern across your bile acid profile, your other lab markers, and your clinical picture. Treat your number as one input in a larger story, not a verdict on its own.

Reference Ranges

There are no universal clinical cutpoints for fecal TCDCA. The values below come from a serum bile acid study using a precise lab technique that separates and measures individual bile acids. They are illustrative orientation only. Your lab measures stool, may use different methods, and will report different absolute numbers. Compare your results within the same lab over time rather than against any specific threshold.

Source: Luo et al., PLoS ONE 2018, serum measurements. These ranges do not directly apply to stool testing, but they show how dramatically TCDCA can shift when liver biology is disturbed. Reported sex and ancestry differences in serum TCDCA exist in the literature but are not consistent enough to apply at an individual level. No clear age effect has been established.

Tracking Your Trend

Bile acids fluctuate with what you ate, when you last ate, your microbiome at that moment, and a long list of other factors. A single fecal TCDCA reading is a snapshot, not a verdict. The intra-individual variability of stool TCDCA has not been formally characterized in published research, which is itself a reason to lean on trends rather than absolute values.

Get a baseline reading. If you are making dietary or supplement changes that target gut or liver health, retest in 3 to 6 months to see whether your number is moving alongside your other markers. After that, at least annual monitoring gives you enough data points to separate real shifts from background noise. Anyone who has gone through bariatric surgery, bile acid therapy, or significant changes in microbiome health should test more often during the change period.

When Results Can Be Misleading

• Recent food and bile acid timing: bile acids surge after meals as bile is released to digest fat. Collection timing relative to your last meal can shift levels meaningfully.
• Stool collection variability: the part of the stool sampled, time at room temperature before sealing, and recent transit time can all influence the reading. Follow the kit's instructions exactly.
• Antibiotics: recent antibiotic use can alter the gut microbes that transform bile acids in the colon and shift the bile acid profile without reflecting any change in liver or intestinal disease.
• Bile acid sequestrants: drugs like cholestyramine bind bile acids in the gut and can change what shows up in stool. They alter the lab number through direct binding rather than through any change in your underlying liver biology.

Decision Pathway for an Abnormal Result

An unusual TCDCA reading in stool is a flag, not a diagnosis. The right next step depends on the rest of your picture. If your liver enzymes (ALT, AST, GGT, alkaline phosphatase) are also elevated, a hepatology workup is reasonable. If you have chronic diarrhea or unexplained urgency, look at the full bile acid panel and consider evaluation for bile acid diarrhea, which is treatable and often missed. If you have known fatty liver, metabolic dysfunction, or a strong family history of biliary cancers, share the result with a gastroenterologist or hepatologist who can put it into context. A pattern across multiple bile acids is more informative than any single one in isolation.